Solubility and Stability Enhancement of Atorvastatin by Cyclodextrin Complexation

References

1. 1.
   1. Loftsson T,
   2. Brewster M. E.

   Pharmaceutical applications of cyclodextrins. 1. Drug solubilisation and stabilization. J. Pharm. Sci. 1996, 85 ( 10), 1017– 1025.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.
   1. Shyam S.,
   2. Bhaskar C.

   Cyclodextrins: Application in different routes of drug administration. Acta Pharm. 2001, 55, 139– 156.

   OpenUrl
3. 3.
   1. Martin E. M.,
   2. Del V.

   Cyclodextrins and their uses: A review. Process Biochem. 2004, 39 ( 9), 1033– 1046.

   OpenUrlCrossRef
4. 4.
   1. Loftsson T.,
   2. Fee O. R.

   Cyclodextrins in solid dosage forms. Pharm Tech. 2003, 176– 180.
5. 5.↵
   1. Viega F.,
   2. Fernandez C.,
   3. Maincent P.

   Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug. Dev. Ind. Pharm. 2001, 27 ( 6), 523– 532.

   OpenUrlPubMed
6. 6.↵
   1. Kerc J.,
   2. Salobir M.,
   3. Bavec S.

   Atorvastatin Calcium in a Pharmaceutical Form Composition Thereof and Pharmaceutical Formulation Comprising Atorvastatin Calcium. U.S. Patent 7,030,151 B2, 4 18, 2006.
7. 7.↵
   1. Black A. E.,
   2. Michael W. S.,
   3. Roger N. H.

   Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Met. Dis. 1998, 26 ( 8), 755– 763.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Kearny A. S.,
   2. Crawford L. F.,
   3. Mehta S. C.,
   4. Radebaugh G. W.

   The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxy acid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm. Res. 1993, 10 ( 10), 1461– 1465.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Higuchi T.,
   2. Connors K. A.

   Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4, 117– 212.

   OpenUrl
10. 10.↵
    1. Saetern A. M.,
    2. Nguyen N. B.,
    3. Bauer-Brandl A.,
    4. Brandl M.

    Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 2004, 284 ( 1–2), 61– 68.

    OpenUrlPubMed
11. 11.↵
    1. Sydyka E.,
    2. Esra S.,
    3. Aktas L. E.,
    4. Ersoy L.,
    5. Ficicioglu S.

    An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal. 2003, 33 ( 5), 1017– 1023.

    OpenUrlPubMed
12. 12.↵
    1. Zingone G.,
    2. Rubessa F.

    Preformulation study of the inclusion complex warfarin- β-cyclodextrin. Int. J. Pharm. 2005, 291 ( 1–2), 3– 10.

    OpenUrlPubMed
13. 13.↵
    1. Mukne A. P.,
    2. Nagarsenker M. S.

    Triamterene β-cyclodextrin systems: Preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2004, 5 ( 1), E19.

    OpenUrlPubMed
14. 14.↵
    1. Wen X.,
    2. Tan F.,
    3. Jing Z.,
    4. Liu Z.

    Preparation and study the 1:2 inclusion complex of carvedilol with β-cyclodextrin. J. Pharm. Biomed. Anal. 2004, 34 ( 3), 517– 523.

    OpenUrlPubMed
15. 15.
    1. Nalluri B. N.,
    2. Chowdhary K. P. R.,
    3. Murthy K. V.,
    4. Hayman A. R.,
    5. Becket G.

    Physicochemical characterization and dissolution properties of nimesulide–cyclodextrin binary systems. AAPS PharmSciTech 2003, 4 ( 1), E2.

    OpenUrlPubMed
16. 16.
    1. Aly A. M.,
    2. Qato M. K.,
    3. Ahmad M. O.

    Enhancement of the dissolution rate and bioavailability of glipizide through cyclodextrin inclusion complex. Pharm. Tech. 2003, 27 ( 6), 54– 62.

    OpenUrl
17. 17.
    1. Ghorab M. M.,
    2. Abdel-Salam H. M.,
    3. El-Sayad M. A.,
    4. Mekhel M. M.

    Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 2004, 5 ( 4), E59.

    OpenUrlPubMed
18. 18.↵
    1. Jacobsen W.,
    2. Kuhn W.

    Lactonization is the critical step in the disposition of the 3-hydroxy 3-methyl glutaryl CoA reductase inhibitor atorvastatin. Drug Met. Dis. 2000, 28, 1369– 1378.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Capello B.,
    2. Carmignani C.,
    3. Iervolini M.,
    4. Immacolata La Rotonda M.,
    5. Fabrizio Saettone M.

    Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: in vitro/in vivo studies. Int. J. Pharm. 2004, 213 ( 1–2), 75– 81.

    OpenUrl
20. 20.↵
    1. Reddy M. N.,
    2. Rehana T.,
    3. Ramakrishna S.,
    4. Chowdary K. P.,
    5. Diwan P. V.

    β-cyclodextrin complexes of Celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS J. 2004, 6 ( 1), 68– 76.

    OpenUrlPubMed
21. 21.↵
    1. Baboota S.,
    2. Agrawal S. P.

    Formulation of meloxicam cyclodextrin complexes incorporated tablets. The Indian Pharmacist 2005, 4 ( 35), 62– 66.

    OpenUrl
22. 22.
    1. Jambhekar S.,
    2. Casella R.

    The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl β-cyclodextrin, and hydroxypropyl β-cyclodextrin complexes. Int. J. Pharm. 2004, 270, 149– 166.

    OpenUrlPubMed